Skip to main content
Clinical Trials/NCT03209362
NCT03209362
Completed
Phase 2

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Repeated Intra-Articular Injection of SI-613 in Patients With Osteoarthritis of the Knee

Seikagaku Corporation10 sites in 1 country80 target enrollmentOctober 19, 2017

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Osteoarthritis, Knee
Sponsor
Seikagaku Corporation
Enrollment
80
Locations
10
Primary Endpoint
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscore Over 12 Weeks
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The objective of the study is to evaluate the efficacy and safety of intra-articular injections of SI-613 compared with placebo for knee OA.

Registry
clinicaltrials.gov
Start Date
October 19, 2017
End Date
November 13, 2018
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Provides their written informed consent.
  • Has a diagnosis at the time of screening of OA of the knee according to American College of Rheumatology (ACR) criteria
  • Is willing to switch to using acetaminophen as a rescue medication

Exclusion Criteria

  • Has a body mass index (BMI) greater than or equal to 40 kg/m2 at screening.
  • Secondary OA
  • Is a female subject who is pregnant or lactating.
  • Is currently hospitalized or has a planned hospitalization during the life of the study.

Outcomes

Primary Outcomes

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscore Over 12 Weeks

Time Frame: Baseline over 12 weeks

Observed VAS of 100 mm; 0 mm meaning no pain; 100 mm meaning extreme pain. Change in score from baseline over 12 weeks was analyzed using a repeated measures Analysis of Covariance (ANCOVA) model.

Secondary Outcomes

  • Change From Baseline in WOMAC Pain Subscore at Weeks 12 and 26(Baseline, Weeks 12 and 26)
  • Change From Baseline in WOMAC Physical Function Subscore at Weeks 12 and 26(Baseline, Weeks 12 and 26)
  • Change From Baseline in WOMAC Stiffness Subscore at Weeks 12 and 26(Baseline, Weeks 12 and 26)
  • Change From Baseline in WOMAC Total Score at Weeks 12 and 26(Baseline, Weeks 12 and 26)

Study Sites (10)

Loading locations...

Similar Trials